ObjectiveColorectal cancer is one of the most prevalent consequences of cancer-bound decease worldwide and it remains one of the leading outcomes of cancer-bound decease. Boron is an important mineral that acts significant function in various biological courses. Some important chemical properties of boric acid support its utility in the treatment of cancer. The aim of this study is to evaluate the antiproliferative effects of boric acid in colon cancer.Materials and Methods This experimental study effect of different concentrations of boric acid on the CCl-233 human colon adenocarcinoma cell lines was investigated, by analyzing proliferation assay (proliferation was applied to the cells for 24, 48 and 72 hours). Proliferation assay was performed using CCK8 Assay Kit. Vascular endothelial growth factor (VEGF) and poly (ADP-) ribose polymerase (PARP) analyses were performed using Sun-Red Human (VEGF) ELISA Kit and Sun-Red Human (PARP) ELISA Kit, respectively. Results As a result of the studies, analysis of the cell viability showed that 50 mM boric acid decreased cell proliferation after 24, 48 and 72 hours. The maximal decrease in cell proliferation was found to occur at 48 hours. Therefore, PARP and VGEF analyses were performed at 48 hours. PARP values were significantly higher in cisplatin (P<0.05). In contrast, PARP levels were significantly lower (P<0.05) at two concentrations of boron (50-100 mM). In VEGF, analysis showed that boron levels were significantly different from cisplatin, but there was no significant difference between control groups. ConclusionIt is proposed that the molecular mechanisms leading to this type of cancer as well as the effect of boric acid on colon cancer should be clarified in more detailed ways for the early diagnosis and treatment of colon cancer.